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line characteristics: Age, Sex, and BMI. We used existing literature and public da-
tasets to estimate the parameters of the model. For the BMI trajectory, we utilized
existing literature on pooled databases of the individuals’ BMI over time. For the
probability of death, we constructed life tables by estimating the 5-year probability
of death using a logistic regression model using data from the National Health
Institute Survey linked with National Death Index (NHIS-NDI) between 1997 and
2005. For costs and QALYs, we useMedical Expenditure Panel Survey Panels 6-10 to
estimate hedonic linear regressions in each period. Costs and QALYs were dis-
counted at 3%. RESULTS: In the base case— for a 45 year-old female—the expected
age of death for baseline BMI of 25, 35, or 45 was 83, 80, and 77, respectively. The
projected difference in discounted lifetime healthcare costs between this non-
obese (BMI 25) person and someone BMI 45 is about $26,000. If the loss inQALYs
were valued at $100,000/QALY, the net economic value loss is projected at $271,000.
CONCLUSIONS: Obesity is associated with higher medical costs, lower quality of
life, and reduced life expectancy. The societal cost of delivering effective weight
loss interventions to obese Americans should be considered in the context of these
lifetime outcomes.
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OBJECTIVES: ITP is characterized by reduced platelet counts and increased risk of
bleeding. Romiplostim, a first-in-class thrombopoietin mimetic, safely increases
and sustains platelet counts in most adult patients with chronic ITP for as long as
needed, while reducing the need for concurrent and emergency medications. We
evaluated treatment costs per overall platelet response with romiplostim  con-
current treatment vs. placebo  concurrent treatment in chronic adult ITP, from a
Public Mexican Healthcare perspective.METHODS: Overall response, defined as 
4 weekly platelet responses (50x109/L ) from weeks 2 to 25, was derived from two
randomized parallel trials with splenectomised and non-splenectomised patients
over period of 24 weeks. All patients were allowed to enter on concurrent ITP
medication (danazol, corticosteroids, azathioprine) and receive rescue medication
(eg, intravenous immunoglobulin). Treatment costs included intervention, rescue
medication and management of bleeding-related events during one year period.
Unitary costs were obtained from the 2010 Official Price List of the Public Health-
care System in Mexico ($MXP). Mean treatment cost per response was calculated
for splenectomized and non-splenectomized patients. RESULTS:Cost per response
was lower for romiplostim compared to placebo. Overall response rates were 79%
for romiplostim and 0% for placebo in splenectomized patients and 88% for romi-
plostim vs. 14% for placebo in non-splenectomized patients. Mean treatment costs
were MXP$574,580 for romiplostim and MXP$301,218 for placebo in splenecto-
mized patients and MXP$402,083 for romiplostim and MXP$180,692 for placebo in
non-splenectomized patients. Cost per response were MXP$727,317 for romiplos-
tim and infinite cost per response for placebo in splenectomized patients and
MXP$456,912 for romiplostim and MXP$1,290,655 for placebo in non-splenecto-
mized patients. Themain cost-offsetswere due to reduced immunoglobulin rescue
use. CONCLUSIONS: Given the limited number of effective therapies in ITP, romi-
plostimdemonstrates an important and cost-efficient option for both non-splenec-
tomised and splenectomised patients for the Mexican Public Healthcare System.
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OBJECTIVES: Thrombocytopenia may prevent chronic hepatitis C (CHC) patients
from initiating or maintaining anti-viral therapy. Eltrombopag is a thrombopoietin
receptor agonist currently undergoing phase III trials for treatment of CHC-related
thrombocytopenia. This study examines the cost-effectiveness of eltrombopag in
CHC patients with cirrhosis and thrombocytopenia.METHODS: A two-part model
was developed to estimate quality adjusted life years(QALYs) gained with and
without eltrombopag for a hypothetical population of 50-year-old, white,male CHC
patientswith thrombocytopenia and cirrhosiswho are otherwise eligible to initiate
anti-viral therapy. A decision tree followed the first 48 weeks of anti-viral therapy
for patients receiving eltrombopag (30,50,or 75mg dose) versus a placebo con-
trolled, wait-and-see (W&S) strategy. Lifetime outcomes of anti-viral therapy suc-
cess or failure were projected using a Markov model. Eltrombopag probabilities
were taken from a Phase II trial; other probabilities and costs were derived from
published literature. Model outcomes are presented as incremental cost effective-
ness ratios (ICERs). A probabilistic sensitivity analysis was performed to analyze
parameter uncertainty. RESULTS: Successive eltrombopag dosing strategies were
associated with incremental increases in cost and QALYs. All strategies were cost-
effective at a threshold of $50,000/QALY gained. The 75mg strategy weakly domi-
nated the 50mg and 30mg strategies and had an ICER of $27,496 compared to the
W&S strategy. Results were robust to variation among input parameters.
CONCLUSIONS: The results of this study support the use of eltrombopag as a
cost-effective option in CHC patients with thrombocytopenia. Patients on eltrom-
bopag aremore likely to complete antiviral therapy, leading to increased quality of
life and decreased future costs over a lifetime. More studies are needed to analyze
the safety of eltrombopag and to provide more accurate estimates of its effect on
platelet counts and patient withdrawal from antiviral therapy.
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OBJECTIVES: This study aimed to assess incremental cost-effectiveness of VMP vs
MPR-R in patients newly diagnosed with multiple myeloma (MM), ineligible for
ASCT, with average age of 70 years. METHODS: A Markov model from US payer’s
perspective was developed to assess cost-effectiveness of VMP vs MPR-R for treat-
ment of MM. The model included seven health states: responses (multiple), treat-
ment-free/maintenance, progression, second-line treatment, and death. Monthly
transition probabilities were estimated from patient-level data (VISTA) for VMP
andMP and frompublished data (MM-015) forMPR-R. Costs included drug,medical,
adverse event, second-line treatment, and resource utilization in 2010 US-dollar
value. State-specific utilities were derived from patient-level EQ-5D using US-spe-
cific weights. Effectiveness was expressed in LYs and QALYs. Costs and effective-
ness were discounted at 3%. ICER was calculated for VMP vs MPR-R over 20-year
horizon (lifetime). In the base case, the MPR-R vs MP hazard ratio (HR) for PFS was
0.499 and that for OS was 1, as the survival benefit with MPR-R vs MP was not
observed in MM-015. One-way sensitivity analyses were conducted for key param-
eters to assess the general robustness of themodel. RESULTS: Base-case results for
VMP vs.MPR-R showed: $119,102 vs $248,358 for directmedical costs; 4.187 years vs
3.409 years for LYs; cost of R maintenance was $107,047. VMP was associated with
reduced costs and better outcomes compared with MPR-R; VMP costs approxi-
mately 50% less than MPR-R and seems to provide slightly more QALYs (0.567) on
average. Sensitivity analyses supported the robustness ofmodel findings and iden-
tified the MPR-R vs MP HR for OS as a key driver; only when this HR was 0.24 did
MPR-R become cost-effective vs VMP at $100,000 per QALY. CONCLUSIONS: VMP
had lower costs and better health outcomes compared to MPR-R. R maintenance
showed little additional benefit.
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OBJECTIVES: Ankle sprain causes walking limitation, pain and consequently, eco-
nomic losses. The purpose of this study was to estimate the cost-effectiveness
from a societal perspective of sequential use of parecoxib/celecoxib for pain man-
agement associated with ankle sprain in adults. METHODS: A Markov model was
performed to estimate health and economic consequences during a time horizon
of 45 days (3-day cycles). Effectiveness measures were: percentage of patients re-
porting pain reduction, percentage of patients reporting50% pain reduction from
baseline, reduction of length of stay (LOS) and reduction in the number of treat-
ment retirements due adverse events. Transition probabilities were obtained from
a meta-analysis employing international published literature. Doses of compara-
tors were: diclofenac (75mg bid) followed by diclofenac (100mg bid); parecoxib
(40mg bid) followed by celecoxib (200mg bid) and ketorolac (30mg qid) followed by
ketorolac po (10mg tid) as the reference. Parenteral and oral forms were adminis-
tered for two and five days, respectively. Resource use was obtained from Social
SecurityMexican Institute databases (n1,395 records). Direct costswere extracted
from institutional official sources and indirect costs from a validated survey ap-
plied to patients. Costs included: hospitalization, drugs, medical procedures, im-
aging, adverse events management, disability benefits, productivity losses, and
out-of-pocket expenses. Probabilistic sensitivity analyseswere performed employ-
ing bootstrapping techniques. Acceptability curves were constructed. RESULTS:
Parecoxib/celecoxib, ketorolac and diclofenac costs per patient were: US$440.77
[95%CI US$425.65-US$455.88], US$526.08 [US$509.97-US$542.20] and US$815.43
[US$790.18-US$840.68], respectively (p0.05). Parecoxib/celecoxib exhibits the low-
est LOS (0.69 days [0.67–0.71] (p0.05)) and number of treatment discontinuations
(16/1000 patients). Acceptability curves showed that parecoxib/celecoxib will be
cost-effective with 90% of confidence at a willingness to pay closer to US$0.
CONCLUSIONS: Parecoxib/celecoxib is the less costly treatment to manage pain
associated with moderate ankle sprain in Mexico; as well it represents a cost-
saving alternative in LOS reduction and treatment discontinuation regarding com-
peting alternatives.
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OBJECTIVES:The treatment guidelines of obesity at theMexican Institute for Social
Security (IMSS) consider the pharmacological treatment together with the change
in health habits a proper option in cases of obese patients (BMI 30 kg/m2). With
the withdrawal of Sibutramine of the mexican market, Diethylpropion (Amfepra-
mone) emerge as a good candidate to fill the void of a scheme to control and reduce
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weight. The main objective is to conduct a pharmacoeconomic analysis to find out
the cost effectiveness of Diethylpropion with diet and exercise. (DEPDaE), com-
pared against Diet and Exercise (DaE) inMexico.METHODS:Thepoint of viewof the
study was the supplier of IMSS health services. The target population were men
andwomen over 18 years with BMI30 kg/m2. Outcomemeasures were the reduc-
tion of weight in kg and Quality Adjusted Life Years (QALYs). The direct costs in the
treatment of obesity were assessed, treatment of adverse events and complica-
tions (Type 2 Diabetes Mellitus and cardiovascular disease). We used a Dynamic,
Stochastic DiscreteModel (DSD) and a univariate and probabilistic sensitivity anal-
ysis was performed. All the quantities expresed in Mexican pesos (MXP) RESULTS:
DEPDaE presented a lower cost and improved the utility and effectiveness when
compared DaE. Incremental cost was $18,361MXP in males and $16,285MXP in
women. Incremental effectiveness and utility was 4.19 kg and 0.10 QALYs in men
and 3.77 kg and 0.08 QALYs in women. ICER pointed the absolute dominance for
DEPDaE. Estimated savings per 100 patients in the IMSS can be $1,697,027MXP if
complemented by a 100% change health habits using DEPDaE. CONCLUSIONS:
The combination of DEPDaE provides a cost effective improvement to the treat-
ment of patients with a risk profile for obesity.
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OBJECTIVES: Fludarabine (F) is amainstay treatment for CLL. Despite the availabil-
ity of an oral formulation with equivalent efficacy and improved patient accept-
ability, many centres use an IV generic formulation assuming it is cheaper. A
cost-minimisation analysis was undertaken on the two formulations. METHODS:
The model assessed oral vs IV F and combination with oral/IV cyclophosphamide
(FC). It included: European acquisition values defaulted to generic prices; body
surface area 1.75m2; mg/m2 dosages oral F 40, IV F 25, oral C 150, IV C 250; dosage
days/cycle F 5 / FC 3 for 6 cycles/patient. Published adverse events rates were
equivalent except for IV administration complications (8% default) and diarrhoea
(oral F 34.6% vs IV F 11.3% Grade 1/2 and 3.8% vs 0%  Grade 3/4)  2% managed
in hospital. Equipment and clinical resource costs were defaulted to published
rates and authors’ centres. A sensitivity analysis assessing minimum and maxi-
mum potential costs was applied. RESULTS: Acquisition costs per treatment
coursewere higher for oral vs IV (F - €5,334 vs €1,313 FC - €3,213.16 vs €894). However
IV costs increased with adverse events (oral vs IV complications mean €0 vs €40,
diarrhoea €1 vs €0) and hospital resource costs (oral vs IV F - €18 vs €4,200, FC- €18
vs €2,520). Direct oral vs IV treatment costs per patient were F - €5,353 vs €5,553
(range €5,334-€5,353 and €5,513-€5,577), FC - €3,232 vs €3,454 (range €3,214-€3,233
and €3,414-€3,478). Modelling oral adoption in 100 patients - 80% IV F / 20% IV FC, a
100% and 90% switch respectively resulted in €19,943 mean cost savings, releasing
funding and resources for improved care and patient throughput. CONCLUSIONS:
Oral fludarabine acquisition costs are higher than generic IV, but cost-minimisa-
tionmodelling demonstrated reduced direct costs with oral fludarabine, while also
being preferred by patients.
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OBJECTIVES: Recent randomized trials (RCT) have suggested erythropoiesis stim-
ulating agents (ESA) reduce mortality in critically ill trauma patients; however ESA
are costly. We sought to determine cost-effectiveness of ESA in this patient
population.METHODS: A decision analytic model was constructed to compare the
use of ESA to standard care in trauma patients admitted to an intensive care set-
ting. Base case costs and benefits at one year were estimated using mortality esti-
mates from available RCTs. One way and probabilistic sensitivity analyses were
conducted for comparison of the base case scenario with 10 and 25 year time
horizons inMarkovmodels.RESULTS: ESAusewas associatedwith a cost per QALY
gained of $74,500 to $81,748 compared with standard care at one year. One-way
sensitivity analyses indicated results were sensitive to changes in mortality risk,
risk of thrombosis, relative risk ofmortality, relative risk of thrombosis, and quality
of life estimates. Cost effectiveness acceptability curves generated from probabi-
listic sensitivity analysis indicated that the probability ESA would be considered
attractive ranged from 35% to 80% over the range of WTP of $60,000 to $120,000.
Consideration of longer time horizons reduced the cost per QALY gained to $9,338 
$5,957. CONCLUSIONS:While the cost per QALY gained with ESA use falls into the
range of currently accepted healthcare technologies funded in Canada, significant
uncertainty exits, particularly long-term survival benefit with ESA use. Further
research into the efficacy and safety of ESA use in critically ill trauma patients is
required prior to widespread use.
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OBJECTIVES: To examine cost-utility of different erythropoietins (epoetin alfa and
epoetin beta) in Russian anemic patients on dialysis.METHODS: Health survey of
patients in dialysis departments of 23 regions. About 1400 questionnaires were
distributed in May - June 2010. Health-related quality of life was assessed with
self-administrated validated version of Russian version of Euroqol-5D question-
naire. Inclusion criteria were age older than 18 years, terminal stage of chronic
renal failure and treatment with dialysis more then 4 months. All patients have
been divided on four subgroups depending on the name of received erythropoietin.
Direct cost contains of cost of erythropoietin, administration cost, cost of iron
supplemention was calculated. RESULTS: 1395 completed questionnaires were re-
ceived by September, 2010. Detailed analysis of antianemic therapy has shown that
85% patients received erytropoetins. There were four the most used drugs: Recor-
mon (epoetin beta) (42%), Eralfon (epoetin alfa) (18%), Epocrinum (epoetin alfa)
(16%), Eprex (epoetin alfa) (9%). Groups were not differ according to the level of
hemoglobin. Average HRQL, assessed with VAS, was not differ significantly be-
tween 4 groups: 0.62 for Eralfon, 0.59 for Recormon, 0.585 for Eprex, 0.56 for Epoc-
rinum. Per year cost of treatment with Eprex was 5 382 USD, with Eralfon – 4 463
USD, with Recormon – 4 204 USD, with Epocrinum – 1 652 USD. Lifelong costs of
treatment with Eprex was 50 017 USD, with Eralfon – 49 098 USD, with Recormon –
48 785 USD, with Epocrinum – 46 596 USD. The cost per QALY was 85 499 USD per
QALY for Eprex, 83 505 USD per QALY for Epocrinum, 82 547 USD per QALY for
Recormon and 75 596 USD per QALY for Eralfon. CONCLUSIONS: Present cost-
utility analyses revealed that in Russian anemic patients on dialysis the most
cost-effective strategy of antianemic therapy among 4 common erythropoietins
was Eralfon with 75 596 USD per QALY.
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OBJECTIVES: Inflammatory Bowel Disease (IBD) is an immune-mediated inflam-
matory disorder which includes Crohn’s disease and ulcerative colitis. The rela-
tionship betweenout-of-pocket (OOP) healthcare costswith productivity is notwell
known in IBD. This study explores the relationship of OOP healthcare costs on
productivity. METHODS: Participants self-identified with IBD and aged 18 com-
pleted an internet-based cross-sectional survey in 1Q2009. Self-reported produc-
tivity loss including absenteeism, presenteeism, overall work impairment and ac-
tivity impairment expressed as impairment percentages, were measured by the
Work Productivity andActivity Impairment questionnaire. Participantswere asked
about IBD-related and overall monthly OOP healthcare costs. Negative binomial
regression models were developed to adjust for age, gender, ethnicity, income,
education, and marital status. RESULTS: 534 participated, 67% were female, 55%
were employed, and 13% were on short- and long-term disability. More than half
(53%) reported annual household incomes between $50-100K, 40% were college
educated. Overall OOP costs were: $0-$50 for 52.6%, $51-$100 for 18.2%, $101-$200
for 15.5%, and  $200 for 13.7%. Among employed, rates of absenteeism, presen-
teeism, and overall work impairment were 9.97%, 16.3% and 20.0%, respectively.
43.2% reported impairment in daily activities. Significantly greater productivity
loss (presenteeism, b 2.79, p 0.0004) and overall work impairment (b 2.78, p
0.0006) were observed among patients with overall OOP costs $200, as compared
to those with OOP costs between $0-50 after adjusting for patient demographics.
CONCLUSIONS: Higher monthly OOP costs were associated with higher work im-
pairment and lower productivity. Shifting healthcare costs to employees maybe
associated with productivity loss. Further research is needed to determine longer-
term impact of OOP healthcare costs on work productivity.
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OBJECTIVES: Hyponatremia (HN) is the leading electrolyte abnormality among
hospitalized patients. In the absence of symptoms, HN is often overlooked as a
condition that warrants aggressive intervention. Though HN is common, little is
known regarding the influence of HN on patient outcomes and healthcare resource
utilization. This study assessed the impact of HN on inpatient total and intensive
care unit (ICU) cost, total and ICU length of stay (LOS), likelihood of ICU admission,
and 30-, 90-, and 180-day readmission. METHODS: Premier’s Perspective® data-
base was utilized to construct a stratified sample of hospital inpatients discharged
between January 1, 2007 and June 30, 2009. HN patients were identified using pri-
mary or secondary diagnosis of HN (n558,815) and were matched to a non-HN
control group (n558,815) using exact matching of age, gender, provider region,
and 3M™ APR-DRG assignment. Matching was further refined using propensity
scores based on additional patient and hospital characteristics and patient comor-
bidities. Cost was analyzed using a multivariate general linear regression model
with gammadistribution and log-link, LOSwith negative binomial distribution and
log-link, and ICU admission and hospital readmission with multivariate logistic
regression. RESULTS: In contrast to non-HN patients, patients with HN had signif-
icantly higher total inpatient cost (9.49%, CI8.99-10.00; p.0001), ICU cost (9.12%;
CI8.04-10.23; p.0001), total LOS (12.24%, CI11.85-12.64; p.0001), and ICU LOS
(11.06%, CI9.60-12.54; p.0001). HN patients were significantly more likely to be
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